How do patients and staff in an opioid agonist treatment service view smoking cessation medications and e‐cigarettes?

Abstract

AbstractIntroductionTobacco use and related mortality is common in people receiving opioid agonist treatment (OAT). Smoking cessation medications are available and e‐cigarettes are increasingly recommended for high risk populations. This study explores experience, knowledge and attitudes around smoking cessation medications (nicotine replacement therapy [NRT], bupropion and varenicline) and e‐cigarettes in patients and clinicians in two public Australian OAT clinics.MethodsCross‐sectional surveys of patients and clinicians and a randomly sampled retrospective medical record review. Patients were recruited through an advertisement in the clinic, and clinicians through advertisement at an educational session.ResultsNinety‐one patients and 10 clinicians completed the surveys. Most patients had at least one quit attempt and 43% were currently trying to quit. There were high levels of exposure to NRT, lower levels with varenicline and very limited exposure to bupropion. Patients considered e‐cigarettes most helpful, but were more likely to consider using NRT. Few patients reported smoking cessation interventions from their clinicians. Most clinicians identified high tobacco use prevalence, considered this problematic, but reported low rates of smoking cessation intervention. NRT was the preferred medication. E‐cigarettes were not considered helpful. Sixty‐six percent of the 140 records reviewed documented patients as smokers. Tobacco cessation medication was rarely discussed or provided.Discussion and ConclusionsPatients report high rates of tobacco cessation planning, but low rates of intervention. Experience of varenicline and bupropion is limited. E‐cigarettes were preferred over varenicline and bupropion. Improving patient's and clinician's knowledge of tobacco cessation medications could improve smoking cessation interventions and uptake of approved medications.